loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Approved Drug Products containing 209337 listed in the FDA Orange Book. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Hikma Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 EUROHLTH INTL SARL (1)

    filter

    01 POWDER;INTRAVENOUS, SUBCUTANEOUS (1)

    filter

    01 RX (1)

    filter

    01 AZACITIDINE (1)

    filter

    01 No (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    • EDQM
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    AZACITIDINE

    PDF Supplier PDF
    URL Supplier Web Content
    POWDER; INTRAVENOU...
    100MG/VIAL
    2020-06-08
    209337
    AZACITIDINE
    RX
    No
    AP
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for FDA Orange Book APPLICATION 209337

    Looking for FDA Orange Book APPLICATION 209337 1

    19

    Hikma Pharmaceuticals, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.

    One of their notable products is AZACITIDINE, with a corresponding application number 209337.

    Regulatory Information RX

    With a dosage strength 100MG/VIAL

    Dosage Form Route POWDER; INTRAVENOUS, SUBCUTANEOUS

    Reference Listed Drug No

    Approved since 2020-06-08

    Therapeutic Equivalence (TE) Code AP

    Post Enquiry
    POST ENQUIRY